OncoMatch/Clinical Trials/NCT05436223
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Is NCT05436223 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Human CD19Targeted T Cells for b-cell non-hodgkin's lymphoma.
Treatment: Human CD19Targeted T Cells — A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20-targeted therapy
the previous use of CD20-targeted drugs ... needed
Must have received: anthracycline
the previous use of ... anthracyclines were needed
Must have received: stem cell transplant
Relapse of B-cell non-Hodgkin lymphoma after stem cell transplantation, regardless of previous treatments
Cannot have received: CAR-T cell therapy
Subjects who have received CAR-T treatment or other gene-modified cell therapy before enrollment
Lab requirements
Blood counts
hemoglobin≥80g/l, neutrophils ≥1.0×10^9/l, platelets ≥75×10^9 / l
Kidney function
serum creatinine≤1.5×uln or creatinine clearance rate≥50ml/min (gockcroftgault formula)
Liver function
total bilirubin≤1.5×uln(gilbert syndrome≤5×uln); alt and ast≤3×uln (ast and alt ≤5×uln in patients with liver metastases)
Cardiac function
cardiac ejection fraction >50%, no clinically significant pericardial effusion detected, no clinically significant pleural effusion detected; baseline blood oxygen saturation>92%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify